Novartis said it returned to sales growth in the second quarter, as momentum from some of its key medicines and recent launches helped the company offset a hit from drugs that lost patent protection.
Novartis said it returned to sales growth for the second quarter, after lower-priced competition in the U.S. for drugs that went off patent weighed on its top and bottom lines in prior quarters. Net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results